Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Translational Development Acquisition (TDAC) Liabilities and Shareholders Equity (2023 - 2026)

Translational Development Acquisition's Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $183.3 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 3.82% to $183.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $723.2 million, a 105.69% increase, with the full-year FY2025 number at $181.7 million, up 3.83% from a year prior.
  • Liabilities and Shareholders Equity came in at $183.3 million for Q1 2026, up from $181.7 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $183.3 million in Q1 2026, with the low at $2021.0 in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $153.5 million across 4 years, with a median of $178.2 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 8659008.31% in 2024 and later rose 3.82% in 2026.
  • Year by year, Liabilities and Shareholders Equity stood at $2021.0 in 2023, then skyrocketed by 8659008.31% to $175.0 million in 2024, then grew by 3.83% to $181.7 million in 2025, then grew by 0.91% to $183.3 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for TDAC at $183.3 million in Q1 2026, $181.7 million in Q4 2025, and $180.0 million in Q3 2025.